Thank you for joining us for the Guardant Health Q2 2020 Earnings Conference Call. I will now hand the call over to Ms. Carrie Mendivil from Investor Relations. Please proceed.

Thank you. Earlier today, Guardant Health released financial results for the quarter ended June 30, 2020. If you've not received this news release or if you'd like to be added to the company's distribution list, please send an email to [email protected]. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section titled Forward Looking Statements in the press release Guardant issued today. For a more complete list and description, please see the Risk Factors section of the company's Annual Report on Form 10-K for the year ended December 31, 2019, and in its other filings with the Securities and Exchange Commission. Except as required by law, Guardant disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information that is accurate only as of the live broadcast, August 6, 2020. With that, I'd like to turn the call over to Helmy Eltoukhy, Guardant's Co-Founder and Chief Executive Officer. Helmy?

Thanks, Carrie. Good afternoon, and thank you for joining our second quarter 2020 earnings call. Joining me today is AmirAli Talasaz, our President and Co-Founder; and Derek Bertocci, our Chief Financial Officer. To start, I hope everyone is in the best of health and in good spirits as we face the continued ramifications of the pandemic. As expected, the impact of COVID-19 created headwinds for the oncology space during the second quarter and not surprisingly, various aspects of our business were affected to varying degrees, which I will review in a bit. That said, in the face of these ongoing challenges, the Guardant team has continued to make substantial progress across our business, presenting new data for our LUNAR-2 assay, announcing 2 new contained diagnostic partnerships and launching our GuardantINFORM platform. Indeed, these past few months have made me more confident than ever in the promise of our platform and the significant opportunity ahead to transform patient care, despite the challenges posed by the pandemic today. I'm extremely proud of the Guardant team for the fire and dedication they have shown in this new environment. The fuel to the fire, so to speak, is their commitment to serve patients and consistent with these values, I will start off our call with a patient story. Recently, a 60-year-old man presented with a brain metastasis and an initial workup identified lung nodules and suspicious lymph nodes. Unfortunately, as oncologists in the community setting have noticed, patients are coming in at more advanced stages due to delays in addressing symptoms as a result of the pandemic. The brain metastasis was the most urgent matter for this patient and brain surgery was performed. The provider was suspicious of lung cancer given the histology of the brain biopsy and the presence of lung nodules, but a lung biopsy following the brain procedure was deemed too risky. His oncologist needed a genomic assessment of his tumor. And while tissue from his brain biopsy was sent off for genomic testing, they were still awaiting results. The provider decided to try a liquid biopsy and sent to Guardant360 at the suggestion of his colleague, a frequent Guardant360 user. Guardant360 quickly identified a MET exon 14 skipping alteration. Based on this result, the oncologist was able to select capmatinib for his first line treatment. Not only does this story demonstrate the importance of the precision oncology paradigm, but it highlights how our liquid biopsy platform is uniquely qualified to address the needs of patients during this challenging time. Turning to our business, we ended the second quarter with revenues of $66.3 million, growing 23% over the second quarter of 2019. Clinical volumes for Guardant360 grew 15% to 13,694 clinical tests compared to the second quarter of 2019. On our last earnings call, I shared that our U.S. clinical volumes were down about 30% exiting the first quarter compared to the average level of clinical samples over the first 10 weeks. And by early May, we had begun to see a slight uptick in sample volume from the lowest points in early April. We continue to see improvement in clinical volumes throughout May and into June and are pleased to report that we exited the quarter with volumes similar to the levels we saw in mid-March prior to the impacts from COVID-19. Through this difficult time, our team was not only able to maintain uninterrupted operations, but was also able to consistently maintain our industry-leading turnaround times for Guardant360 of 7 days or less. Diving deeper into clinical volumes, growth recovered more quickly in community hospitals compared to the academic setting. Additionally, we saw a rapid shift towards telemedicine. Before the pandemic, oncology visits very rarely used telemedicine, with just a few percent of visits performed virtually. Over the past few months, this trend has reversed itself to protect advanced cancer patients, who are an extremely high-risk population, from exposure to COVID-19. As a result, there have been fewer physical visits to oncology offices and fewer new diagnoses, factors that benefit the increased use of liquid biopsy testing, especially when coupled with our mobile phlebotomy services and digital offerings. While these trends are encouraging, we believe that the path of recovery is likely to remain uncertain in the near term. Since the end of June, we have seen a resurgence of COVID cases in some regions across the U.S., and it's unclear how a second wave of closures resulting from the pandemic may impact our clinical volumes through the end of the year. Turning to our biopharma business, volumes declined 47% year-over-year to 2,805 tests. This was counterbalanced by 29% year-over-year growth in development services revenue of $15.3 million. On the whole, we remain pleased with our biopharmaceutical business. AmirAli will give further detail in a few minutes. Across the board, we remain unwavering in our commitment to serving patients in advanced cancer settings and have continued to shift the market to a blood-first paradigm for genotyping. At the end of 2018, we outlined 3 key catalysts that will be critical to shifting the market to a blood-first paradigm: first, demonstrating concordance between liquid biopsy and tissue testing; second, Pan-Cancer Medicare coverage; and finally, FDA approval of Guardant360 with a Pan-Cancer tumor profiling label. In the first quarter, we began to see benefits from Pan-Cancer Medicare payments outside of non-small cell lung cancer, and we are looking forward to achieving the third catalyst with the approval of Guardant360 for all solid tumor types. We believe FDA approval will help to accelerate wider adoption of guideline-recommended genomic profiling, increasing the number of advanced cancer patients who receive potentially life-changing treatments. Specifically, we expect FDA approval to strengthen reimbursement by advancing conversations with private payers and further improving existing Medicare coverage; extend momentum for our companion diagnostics business through increased opportunities to work with biopharma in the clinical setting; and over the medium to long term, advance the use of Guardant360 with physicians who have been slow to adopt CGP. Looking ahead, we continue to believe that the unique opportunity we have here at Guardant will allow us to serve patients well beyond those in advanced stages of the disease. During the quarter, we completed a follow-on offering, raising approximately $355 million of net proceeds, bringing our cash, cash equivalents and marketable securities total to $1.1 billion. We intend to use these funds to accelerate development in our LUNAR program and pursue the large market opportunities in front of us. I'm incredibly proud of the outstanding efforts across our organization, and the last few months only reaffirm my belief that we will come out of this period even stronger as a company. With that, I will now turn the call over to AmirAli for more detail on our biopharma business and our LUNAR program.

Thanks, Helmy. I hope all of you and your families are staying safe and healthy. Turning first to our biopharma business, as Helmy mentioned, we had a strong quarter for our CDx development services, offset by lower sample testing volumes. Starting with biopharma volumes, we have always noted the likelihood of ebbs and flows in our biopharma business. Back in February, on our 2019 year-end earnings call, we anticipated that biopharma volumes would be lighter in the first half of the year. In addition to these anticipated fluctuations, COVID-19 has clearly impacted the sample testing in prospective studies and also the timely shipment of biobank samples from retrospective studies. Looking ahead to the next couple of quarters, we expect that the effect of COVID-19 may continue to ripple through biopharma sample testing volume. However, through conversations with our biopharma partners, we continue to see robust future demand for sample processing, especially using GuardantOMNI. Conversely, we experienced strong growth in our companion diagnostic business, which speaks to the progress we are making in our CDx product development activities and the robust interest from our biopharma partners. We recently announced 2 new CDx partnerships: in early July with Janssen for amivantamab, an investigational EGFR-MET bispecific antibody being studied in the treatment of non-small cell lung cancer patients with EGFR exon 20 insertions, which comprise 4% to 12% of non-small cell lung cancer patients with EGFR mutations. We are encouraged that our partners are recognizing the value of comprehensive testing to find these patients and to support the broad commercial penetration to accelerate uptake of these types of target therapies from the first day of approval. And last week, we announced the CDx collaboration with Radius Health for elacestrant, our first companion diagnostic program in breast cancer. Given the high prevalence of bone metastases in advanced breast cancer disease, our Guardant360 liquid biopsy can help overcome the challenges of bone biopsies by identifying significantly more actionable biomarkers, including ESR1 mutations, which are being studied in the Radius EMERALD trial. We are extremely pleased by the progress of our companion diagnostics business to date and are encouraged by the healthy pipeline of other CDx discussions underway. Our companion diagnostic program supports the critical expansion of targeted therapies, which we believe will be one of the most important drivers of Guardant360 clinical adoption. 2020 has seen more new targeted therapies approved by the FDA than prior years and we are already seeing the positive effects in clinical volumes for indications with recent drug approvals, for example, in prostate cancer. We also remain deeply cognizant to continue generating robust data to further improve cancer diagnosis and treatment. In late June, we launched a real-world clinical genomic platform, GuardantINFORM, to help accelerate research and development of the next generation of cancer therapeutics. Each Guardant360 test provides critical genomic information on various tumor profiles and we have now collected this genomic information from more than 100,000 patients to date. GuardantINFORM combines this robust genomic data with the identified clinical information for each patient. This clinical genomic data set offers our biopharma partners real-world insight into how patients are treated based on their mutation profiles, as well as patterns of drug resistance and tumor evolution. The most notable applications for GuardantINFORM include targeted drug development and label expansion, clinical trial optimization by incorporating real-world clinical genomic data into trial design and control arm development, as well as post-marketing studies. Now turning to our LUNAR program. We are continuing our research on clinical development activities at relatively full capacity. We have expanded our trial site in ECLIPSE to over 130 sites. Patient enrollment began to reaccelerate in late June, following lulls throughout April. In fact, June was a record month of enrollment and we have continued to see growth subsequent to quarter end. Overall, we are very pleased with our progress, particularly during these difficult past few months. We continue to believe we will complete enrollment within the 24-month time frame announced last November. After ECLIPSE, we are also developing robust data in support of our LUNAR-2 assay. At AACR, we shared data from a new patient cohort that demonstrated improved performance of LUNAR-2 assay to detect early-stage colorectal cancer in average risk adults. Our assay achieved 90% sensitivity and 94% specificity in detecting early-stage colorectal cancer and even higher specificity when restricting analysis of the controls to those who are negative for colorectal cancer by colonoscopy. Finally, on our last earnings call, we shared details on our efforts to develop a diagnostic assay for SARS-CoV-2. We recently filed for an Emergency Use Authorization of our NGS assay and are currently using it in-house for surveillance testing of Guardant employees. As an essential business, weekly COVID-19 screenings have been critical to both keeping our employees safe and maintaining business continuity. We continue to believe that similar screening programs will be an important component of the sustained reopening of the economy and educational systems across the U.S. With that, I will now turn the call over to Derek Bertocci for more information and details about our financials.

Thanks, AmirAli. Revenue for the second quarter of 2020 totaled $66.3 million, up 23% from $54 million in the prior year quarter, but down $1.2 million or 2% from the first quarter of 2020. The increase from Q2 2019 was driven by an increase in precision oncology testing revenues resulting from significant increases in average selling price or ASP per test as well as higher development services revenue. The decline from the first quarter of 2020 was driven by lower test volumes caused by the COVID-19 pandemic, mostly offset by higher development services revenue. Total precision oncology testing revenue for the second quarter was $51 million, comprised of $39.6 million from clinical tests and $11.4 million from biopharmaceutical tests. Precision oncology revenue from clinical tests included $2.6 million in revenue received from Medicare for samples processed in 2019. Given the age of the samples associated with this revenue, we do not believe it to be indicative of ordinary course of operations. Second quarter clinical precision oncology volume totaled 13,694 tests, up 15% from 11,875 tests in the prior year quarter, but down 10% from 15,257 tests in the first quarter of 2020 due to the COVID-19 pandemic. Clinical precision oncology ASP was $2,893 in the second quarter of 2020, up 57% from $1,839 in the prior year period and up 16% from $2,489 in the first quarter of 2020. The 57% increase in clinical ASP over the prior year quarter was due principally to the reimbursement from Medicare for testing of non-lung cancer samples in addition to lung samples starting in March 2020, with a modest increase in reimbursement from commercial insurers and $2.6 million received from Medicare for samples processed in 2019. In Q2, the processing of samples reimbursed by Medicare stabilized under the new coverage policy, and as a result, we recorded revenue on approximately 85% of Medicare samples in Q2, up from approximately 75% of Medicare samples in Q1. This increase in Medicare reimbursement plus a modest increase in reimbursement from commercial insurers, as well as revenue from Medicare for samples processed in 2019, resulted in a 16% increase in clinical ASP in Q2 over Q1. Precision oncology revenue from biopharmaceutical tests in the second quarter totaled $11.4 million, down 44% from $20.2 million for the second year quarter and down 49% from $22.3 million in the first quarter of 2020. Second quarter pharma precision oncology volume totaled 2,805 tests, down 47% from 5,285 tests in the prior year quarter. As expected, second quarter volume was lower than the prior quarter, down 47%, due mainly to the impact of the COVID-19 pandemic on customer programs. ASP was $4,054, up 6% from $3,827 in the prior year period, but down 4% from $4,230 in the first quarter of 2020. The ASP was driven by changes in the proportion of total biopharmaceutical tests using the GuardantOMNI test, which has a higher selling price than the Guardant360 test. Development services revenue in the second quarter totaled $15.3 million, up 29% from the prior year quarter and up 111% from the first quarter of 2020. The increase was primarily due to companion diagnostic revenue, including programs with Amgen and Janssen, which boosted development services revenue in the first half of 2020. Gross profit for the second quarter of 2020 was $43.9 million compared to a gross profit of $37.1 million in the same period of the prior year and $47 million in the first quarter of 2020. Gross margin in the second quarter was 66% as compared to 69% during the second quarter of 2019 and 70% in the first quarter of 2020. The decline in gross margin compared to the second quarter of 2019 was primarily due to a lower gross margin on development services revenue, the result of normal variability across programs. The decline in gross margin compared to the first quarter of 2020 was due principally to the lower ASP for pharma testing, plus an increase in overhead cost per unit due to the decline in total volume of samples tested. Total operating expenses for the second quarter of 2020 were $98.5 million, an 88% increase from $52.4 million in the second quarter of 2019 and up 20% from $81.9 million in the first quarter of 2020. R&D expenses for the second quarter of 2020 were $36.3 million compared to $19.5 million in the second quarter of 2019. The increase was primarily attributable to increased expense for our LUNAR programs, including the ECLIPSE clinical trial, our FDA submission for Guardant360 and other research and development programs, including development of our COVID-19 test. Sales and marketing expenses for the second quarter of 2020 were $25.0 million compared to $19.4 million in the second quarter of 2019. The increase was due to growth in sales marketing staff, plus spending on programs to increase education and awareness about liquid biopsy. General and administrative expenses for the second quarter were $37.2 million compared to $13.4 million in the second quarter of 2019. G&A expenses for the second quarter included $18.3 million in stock-based compensation related to market-based restricted stock units granted to the company's founders on May 26, 2020. The remaining increase in G&A expense was $5.5 million, which was primarily due to additional staff to support the growth of the company, legal expenses, and the cost of compliance with the requirements of becoming a large accelerated public filer with the SEC. The market-based restricted stock units were designed to focus the founders on the long-term operational and strategic development of the company, including the successful development and commercialization of the key LUNAR programs. The design of the market-based restricted stock units builds upon the successful company performance that the founders have led to date and the Board believes the market-based restricted stock units further align the founders' interests with those of the company's long-term stockholders because the vesting will depend on creation of significantly enhanced stockholder value over the following 7 years. Net loss attributable to Guardant Health common stockholders was $54.6 million or $0.57 per share compared to $11.6 million or $0.13 per share in the second quarter of 2019. We ended the second quarter of 2020 with $1.1 billion in cash, cash equivalents and marketable securities. Beginning this quarter, we added disclosure of adjusted EBITDA, a non-GAAP financial measure, to our financial reporting to assist management and investors in evaluating the performance of our core business by removing the impact of income or expenses attributable to material noncash items, specifically stock-based compensation and fair value remeasurements due to the subjectivity, management judgment, and market fluctuations involved in these amounts. We exclude certain other items because we believe that these incomes or expenses do not reflect expected future operating expenses. Additionally, certain items are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. You will find a detailed presentation of non-GAAP adjusted EBITDA and a full reconciliation to GAAP net loss attributable to Guardant Health, Inc. common stockholders in our Q2 2020 results press release and quarterly 10-Q filed with the SEC. Our use of adjusted EBITDA as a non-GAAP financial measure is not intended to be considered in isolation from as a substitute for or as superior to the corresponding financial measures prepared in accordance with GAAP. Non-GAAP adjusted EBITDA was a loss of $25 million in the second quarter of 2020 compared to $9 million in the second quarter of 2019. The impact of COVID-19 created headwinds for the oncology space during the second quarter and due to its unpredictable evolution, we do not believe that we can reasonably estimate the magnitude or duration of specific impacts on our business. Accordingly, we are not reinstating financial guidance at this time. As Helmy mentioned, we exited the second quarter with clinical test volumes similar to the levels we saw prior to the impacts from COVID-19. That said, we believe the effects from COVID are likely to continue to impact the oncology space in the near term and we anticipate third quarter clinical volumes will be up modestly from the first quarter. Clinical precision oncology ASP in the second quarter was $2,702 when we exclude the $2.6 million of revenue received from Medicare for samples processed in 2019. We expect this clinical ASP to remain steady through the balance of 2020. As AmirAli mentioned, we expect that the effects of COVID-19 may continue to impact biopharma sample testing volumes through the second half of the year. Nonetheless, our customers continue to demonstrate strong interest in our capabilities, and we saw record development services revenue in the second quarter. That said, given the lumpiness of our CDx programs, we do not expect development services to remain at this record peak for the second half of 2020. At this point, I would like to turn the call back to Helmy for closing comments.

Thank you, Derek. Before closing, I want to again thank our team at Guardant for the strength, dedication, and effort they have shown, particularly over the past few months. In these unprecedented times, I have even more confidence in the value that liquid biopsy can bring to the cancer treatment paradigm. We are well prepared operationally, financially, and strategically to navigate through this challenging period, and we remain focused on our long-term opportunity ahead of us to transform cancer patient care. With that, we will now open it up to questions.

Our first question comes from Mr. Doug from Cowen.

Starting on clinical testing revenue, that was up sequentially, as you know, quarter-to-quarter. I think a lot of folks, including me, were expecting a decline, keeping in mind how you exited Q1. And that's encouraging and your commentary is also really encouraging regarding how you exited the quarter and what you're looking for in Q3. What I'd like to dig in on a little bit more is, where have you seen the recovery most? I mean I know you talked about academic centers versus the community. But I guess if you could cut it a different way and talk about existing accounts versus new accounts. I'm just wondering if you've started to be able to be more successful in adding new accounts over the course of the quarter as the world started to open up a little bit more. I ask because in some ways, it would be great to hear that you are able to, once again, open more accounts. But in other ways, if you're still challenged with that metric, it could be argued that the rebound in same-store sales is all the more impressive.

Yes. It's a great question, Doug. This is Helmy. It's really interesting when you look at the data. Clearly, we've been in the market now for 5 or 6 years, over 7,000 oncologists out of the 10,000 or 12,000 have ordered our test at least once. And so the majority of the market does have exposure to Guardant. They have used it at least once, and that's where we believe we have an advantage in this time. We think this sort of time period of uncertainty and lack of access, at least face-to-face, really favors incumbents in this space, of which we are in the liquid biopsy testing arena. And so we have seen and continue to see the addition of new oncologists, but the majority of our business is really catering to existing clients and customers and those that may have only sporadically used our services in the past and getting them to use it more consistently. And to give you a little bit of color, we track a lot of metrics in our business. And I can tell you that June was a record month for us in terms of the number of unique orders of physicians in that month. So we did see, I think, fundamental progress in terms of the KPIs we look at underlying those numbers. And so we do see some certainly positive signs of recovery. That said, we are seeing certain regions that are closing down again. There are clearly many hotspots that are raging on, and that has an impact as well. There is some fatigue going on in terms of virtual consultations and so on, in terms of these physician offices. And so it's something we're continuing to monitor, and we see the ebbs and flows regionally. But I think the underlying message is that we think we're building differential strength, I would say, in terms of the landscape as a whole, in terms of really the compatibility of our offering and the advantages of our offerings, amidst the backdrop of COVID and the challenges that it presents.

Okay. Super helpful, Helmy. AmirAli walked through some of what you released during the quarter on LUNAR-2, some nice data updates. I'm just wondering when we should expect the next data release? And kind of building off of that, it's encouraging and frankly, maybe even a little bit surprising to hear that ECLIPSE is getting going in terms of enrollment and site opening so quickly. That's good news for you, and frankly, in terms of what it implies about what's going on with colonoscopies, I think that's a good sign for all of us. That being said, I'm just wondering, given the momentum you have there, are the original timelines in terms of when you'd expect completion and readout still intact? Or at this point, should we be thinking that there is going to be at least 1 to 2 months, maybe 3 months delay, given where you are right now?

Yes. So regarding data presentation, Doug, you can expect in all majority of major conferences, oncology or related GI congresses, we would have some kind of presence in terms of optics. Regarding ECLIPSE, actually, we are very pleased with our progress. In fact, during the days that patient enrollment was slowed down because of COVID, we put a lot of energy behind bringing new sites on. And I'm very happy that we have over 130 sites. By the end of this quarter, we are going to basically reach our 150 site target that we have for ECLIPSE. The month of June was our record month in Q2, and on the quarter, we find July was even better in terms of enrolling patients in the trial. And we do believe that we can finish this study within the original time frame that we mentioned last November, which was within the 24 months from SPI. And we think still we can finish the study even during this environment within the time frame we mentioned earlier.

Okay. Super helpful. Last one, and then I'll leave it to others. Really pivoting to a completely different topic. I mean I think a lot of us, or at least I tend to think of Guardant as being primarily focused on internal development of products and advancement of internally developed products. That said, the balance sheet is in a really good spot. More broadly, there has clearly been a pickup in the pace of industry consolidation. I'm just wondering if there is any change in how you would describe your appetite and your readiness for more material M&A?

Yes. That's a great question. I think certainly, all of that is on the table in terms of having the balance sheet that we have right now. We obviously have done some small acquisitions in the past, but I think if we think about the commercial channel that we have built, the product portfolio we have, and where we're going in terms of the market, there is certainly a place for inorganically adding to that and increasing leverage in terms of the core competencies we have in our business. And so it's something that we're certainly open to, and we continue to look at opportunities.

And our next question comes from Mr. Puneet Souda from SVB Leerink.

Great. So first one on biopharma revenue, and thanks for the details there, AmirAli. Appreciate those details. So I think the important question there is, despite the impact you're seeing due to COVID and prospective samples and the biobank retrospective samples, what would be helpful is if you can help us understand your view on the underlying studies that are driving those samples to you. Do you think those studies are simply delayed? Or is there any fundamental change in those studies? If you could clarify that and provide us, if you can, in terms of when do you expect sort of those samples to return back to you and into the second half or maybe even later.

So the experience is actually in light of what has already been known in terms of prospective studies sponsored by pharma companies on our prospective trial side. And what also we experienced is some of the major pharma companies are putting a lot of attention into COVID-19 vaccine development and they're taking a fresh look into their pipeline activities. So having said that, we are very pleased with all the conversations we have across many pharma companies around the utility of our products, especially around GuardantOMNI. We still expect that what we experience with COVID-19 is going to ripple through the rest of the year, at least for a couple of quarters. But we are optimistic about the future and all the conversations that we had around our portfolio of products, especially OMNI.

Yes. I mean let me just add one thing. This is Helmy here. I think we're seeing there very good underlying signs in terms of the business. The pipeline is progressing very strong, as well as diversification in terms of the types of partners that are using OMNI and kind of deepening use of that test. So all the kind of underlying metrics we look at are looking good in our view.

Okay. That's great. And if I could have a follow-up on in terms of your LUNAR-1 program, can you elaborate on where you stand on different efforts? I know you're in a number of biopharma collaborations and partnerships are ongoing, there's the COBRA trial that you have invested in, and a few other studies. Maybe just give us a sense of where that stands and then potentially, when can we see that product in recurrence monitoring markets this year or the next? If you could provide any color on that. And then I have a small follow-up.

Yes. As you mentioned, our LUNAR-1/MRD product, initially, we had an RUO version of it, then we had the clinically validated version of that product for CRC, which we are running currently a few trials based on that. And I'm pleased actually with the solid progress that we're making on the R&D side. We have been working for a while to expand our MRD platform technology from basically a CRC device or CRC assay to really a multi-cancer type. So pleased with all the progress that the team has made on that front, and please stay tuned about some data sharing around that platform, which is around multi-cancer MRD units.

Okay. Great. And last one, if I could, on COVID testing. I recall you were working on a differentiated high-throughput platform, and thanks for the update on that in terms of filing the EUA. Anything you can provide in terms of the volumes per day that system can produce, or cost or turnaround time, and maybe potential pricing, if you can?

Yes, we filed our current EUA for the COVID test a few weeks ago. We are in discussions with several potential partners to expand the clinical use of the test beyond just Guardant employees and some limited activities we currently have. The technology platform is designed for high throughput, and we are implementing a high-throughput operation. However, we don't view COVID testing as a new business line for us; we see it as a social responsibility. The partners we are considering are aligned with our mission and recognize the value we want to provide in this field. Additionally, we are ensuring that this initiative does not result in a financial loss for Guardant, but our priority remains on social responsibility rather than turning it into a new revenue stream.

Our next question comes from Tycho Peterson from JPMorgan.

Helmy, on the reimbursement front, you've brought up for CMS, a number of CMS payments for non-lung. Can you just give us a sense of what percentage of the payments today from CMS are non-lung? And I guess, how do you think about that trending until you have the FDA approval?

Yes. So Tycho, approximately 85% of our Medicare samples are covered now under our current reimbursement from Meridian. And whether it's lung or non-lung, it's about the same. So I think really, the way you want to think of it is most all of our Medicare samples are covered now. There is an opportunity, with the FDA approval on the NCD, to have a slight increase in that. But at 85%, there is not a huge amount left to improve there.

Okay. And then, Derek, on the development services side, you noted the milestone component for CDx. Can you just talk about how significant the milestone piece was in the quarter?

We are making progress towards our milestones. It's important to clarify that we don't recognize revenue based on individual milestones; this is a bit of a misunderstanding. We have been moving forward steadily. We had many active programs during the quarter, which led to significant progress. As is typical with biopharma programs, there are ups and downs, but this quarter was particularly strong for our companion diagnostics revenue, which constitutes the majority of our development services revenue.

And then just one last one, following up on the question earlier on LUNAR-1. We've been hearing more about some off-label use. I guess as we kind of think about the commercialization strategy here, you've got the research-use only product and then the clinically validated, as you mentioned. Can you just talk on how material you think LUNAR-1 could be for you guys going forward? And to what extent you're making investments in the channel there to roll it out more broadly?

We are very enthusiastic about our investment levels. The team is dedicated to this program. We believe that a key requirement in the MRD space is demonstrating clinical utility to enhance clinical adoption in the market. We've been engaging with key opinion leaders who are experienced with our Guardant360 product concerning MRD. While we are having ongoing discussions about investigational studies, we prefer not to simply launch the current clinical-grade test without strong clinical evidence. Instead, we focus on generating solid clinical data before entering the market, rather than releasing a product and then trying to convince others of its benefits. In the long run, we believe our approach to the MRD assay has the potential to transform the oncology patient journey, connecting our advanced cancer treatment options with our early cancer detection initiatives. We are very optimistic about this and are increasing our investments in this area.

And our next question comes from Ms. Ivy Ma from Bank of America.

This is Ivy on for Derik today. Firstly, on Lunar-2, just wondering if you had any initial conversations with the CMS, since there are a lot of companies working on pan-cancer early detection these days. So wanted to see if there is any feedback on pan-cancer reimbursement or multi-cancer reimbursement? Or how are you thinking about reimbursement for multi-cancer in general?

In our LUNAR-2 CRC screening program that we have, we've been obviously in touch with the agency, FDA and national CMS, both sides. I think we have a good picture of what it takes for FDA approval and national reimbursement on the Medicare side. One of the reasons that actually Guardant's strategy is to go after CRC screening first and maybe think a follow-on with multi-cancer screening down the road is one of the reasons is reimbursement. Besides the clinical value, unmet need and technological advantages that CRC has, we believe that the reimbursement pathway for CRC-only screening is in fact very different than multi-cancer and there is good pathway for it and claim path for potential FDA approval and national CMS coverage policy. On the multi-cancer side, there are a lot of conversation on workshops, I'm pretty sure you guys are familiar with. It's not easy. So we have to see what's going to happen on multi-cancer side. But we are bullish about our strategy of going to market with the CRC device.

Great. And then on biopharma, we're seeing a lot of companies entering the liquid biopsy space. So I wanted to see if you're seeing more competition for OMNI and how does that shape the revenue trajectory going forward? And then if there is any quantifying color you could offer on how to look at the companion diagnostic line going forward, it would be super helpful.

I guess I can jump in. This is Helmy here. I would say that from a competition point of view, the liquid biopsy space has always had dozens of companies in it from even 8 years ago when we started, and many of those companies still exist. Some of them have gone, and there are new companies that have come in. I would say from a competitive point of view, OMNI is really, I think, head and shoulders above any other offering we see in the space. And so that's not something we frankly see a lot of in terms of competitive noise, especially with respect to OMNI. I think we're much more, I would say, focused and laser-focused on the evolution of the therapeutic pipeline and where that's going and continuing to meet really the requirements in terms of the types of biomarkers that are of interest to our biopharma partners. And so that's really what we're focused on, in terms of really listening to our customers and moving and advancing our offerings in step with that.

Great. And lastly, if I may, on G360, could you update us on the FDA approval situation? And how that conversation has been going? I know there are some delays due to the whole COVID situation, but I wanted to see if there is any updates? Appreciate the color.

Yes. I don't think we experienced any slowdown in our FDA traction due to COVID. We are very pleased with the progress we've made, and based on all the conversations, I believe we are very close. So please stay tuned.

And our next question comes from Patrick Donnelly.

Helmy, regarding the second wave of COVID, you mentioned noticing a slight decrease in volume. Could you explain how significant this pullback is? It seems you aren't overly worried, considering the guidance you provided, but I'm interested in your thoughts on the impact of the second wave and your confidence in the outlook moving forward.

Yes, it's a great question. I mean, certainly, nowhere near as close to, I think, the first wave and the impact that was there. I think the challenge with the first time was it was the first time, by definition, a lot of these offices have been dealing with this kind of situation. And so there was just a lot of learning in terms of how to deal with this sort of new normal. We see certainly a lot more resiliency in terms of impact of the second waves and reclosures and so on. And so I would say these are, I would say, minor perturbations regionally as you see some of these closures and some of the orders that are going into place regionally. So it does have an impact, and that's why I said I think it's difficult to forecast. Obviously, if you have a lot of these happening simultaneously through multiple parts of the country, then that's certainly going to have some negative impact on new diagnoses, patients coming in, and so on and so forth. But we've been seeing these kind of ripple through kind of in different parts of the nation and then kind of come back. And so it's certainly less severe so far than what we saw in March.

That's good to hear. And then maybe just one on mobile phlebotomy. I know you talked about that being a good opportunity in Q2 and even beyond as maybe the market focus shifts a little bit towards that. How did that trend relative to expectations? And just your go-forward view on that side as well?

Yes, as I think we mentioned in the last call, we certainly saw certain regions that leverage that offering quite a bit. That said, it's just that the very nature of liquid biopsy is it's so much simpler than a tissue biopsy-based approach. If you think about the coordination of multiple medical specialties, whether it's pathology or surgical oncologists, or interventional radiologists, the fact that you essentially can empower oncologists with the ability to identify biomarkers through a simple blood test by itself and by its very nature is very well suited to the practical realities that COVID imparts on the space right now. And so, even that alone, with that mobile phlebotomy, is something that's a huge advantage and something very beneficial to physicians. But clearly, there is going to be a subset of patients that find it very difficult to come in, and that's where mobile phlebotomy has been really key in terms of being able to provide a complete offering for really the majority of patients that an oncologist may have. So it's been something that's very synergistic with ease of use of liquid biopsy itself. Clearly, our turnaround time is sometimes half or a third of other tissue-based approaches. And so you really just can't beat that holistic offering, in our view, compared to some of the other approaches of getting that information.

And our next question comes from Max from Canaccord.

This is Max Masucci. So the supply of COVID-19 testing in the U.S. is still well below demand. The U.S. is conducting about 700,000 COVID tests per day by our estimates, which is a bit underwhelming compared to, say, China, which has capacity to process around 5 million tests per day. So what role or magnitude do you think you can play in COVID-19 testing, now that testing is becoming more widely available for asymptomatic individuals versus the early prioritization of testing for health care workers and first responders?

Yes, that's a great question. We are definitely providing weekly testing for our employees at Guardant. We have found it essential for maintaining business continuity, ensuring employee safety, and navigating the challenges posed by the ongoing pandemic. We recognize the importance of testing for surveillance and asymptomatic individuals, and we are actively exploring this further. We are in discussions with various partners about the potential to contribute to the current undersupply of testing. We will keep everyone updated as we make progress.

Great. And then on the sales force, can you just share how your sales force is adjusting to the COVID-19 virtual environment? What sort of initiatives or targeting strategies are sales reps having success with?

Yes. So I think it's a lot of what we outlined, I think in our previous earnings call. It's really the fact that we're able to do a lot of consultations online through Zoom. We're able to employ our medical affairs team to essentially help with interpretation of reports, obviously over Zoom or over teleconference as well as the mobile phlebotomy services that were brought online. We have other kind of financial assistance-type programs that are specifically tailored to those affected by COVID. And so we found that overall offering was very helpful in terms of really supporting physician offices in their time of need to get through some of these kind of challenging times. We believe we were one of the earlier companies to provide that kind of suite of services to many of these offices, and I think that really helped us in terms of achieving the kind of rebound that we saw during the quarter.

And our next question comes from Mr. David with Guggenheim Securities.

This is David Westenberg. So my first question is with Keytruda's approval in TMB-high patients, does that maybe change the look in terms of the ramp for GuardantOMNI? And if it doesn't, can you at least talk about the appetite for larger panels from oncologists?

So currently, actually, the clinical product that we have, Guardant360 for oncologists order, does not provide TMB score, but GuardantOMNI, which has been a product that we opened up to our pharma companies, so far has been able to do that. We've been working with a bunch of pharma companies who were investing heavily on the TMB side, not just TMB, even on the other kind of biomarkers that we have in the GuardantOMNI panel. And still, we see there is a lot of excitement. And the conversation that we have around GuardantOMNI is pretty robust about what's going to happen within the next couple of quarters based on COVID, but the conversation around GuardantOMNI has been solid, and one of the drivers has been TMB.

Got it. Now just a quick question for Derek. As we plan for the second half of the year, is there anything to highlight regarding comparisons? I know you've had strong quarters and possibly some back payments from certain payers. I want to ensure our forecasts are accurate for the second half of the year as we consider year-over-year comparisons. I'll take the rest offline.

Sure. So what we tried to do is give you nuggets of information. We expect a modest increase in volume, clinical volume in Q3 compared to Q1, so not comparing to Q2, which is obviously a down quarter. Going all the way back to Q1, we're expecting modest volume increase in Q3 in clinical. We also indicated that for ASP purposes, you want to pull out the impact of that revenue we earned from samples processed in 2019. There were some changes in the Medicare interpretations of the NCD, which allowed some prior samples to get billed and reimbursed. So you shouldn't assume that. So I gave you a $2,700 ASP for you to use. And then we talked about the biopharma. It was a record quarter for development services, probably won't have a record quarter every quarter.

And that is all the questions we have at this time.

Thank you, everyone, and look forward to talking next quarter.

And ladies and gentlemen, this does conclude today's conference call. Thank you very much for your participation. You may now disconnect.